Jorveza 0.2 mg/mL oral suspension For children and adolescents aged 2-17 years

Licence holder

Dr. Falk Pharma GmbH (all products →)

Active substance

Budesonide

Dosage form

Oral suspension

Route of administration

Oral use

ATC code

A07EA06

First authorised

08/04/2026

Prescription status

Product subject to prescription which may not be renewed (A)

Supply

Supply through pharmacies only

Legal basis

Full application (Article 8(3) of Directive No 2001/83/EC)

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.